NCM
ORIC icon

NEXTBio Capital Management’s Oric Pharmaceuticals ORIC Stock Holding History

NEXTBio Capital Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.65M Buy
706,124
+182,505
+35% +$1.65M 3.52% 10
2026
Q1 		$6.63M Sell
523,619
-92,101
-15% -$1.05M 3.08% 13
2025
Q4 		$5.04M Buy
+615,720
New +$7.09M 2.95% 14

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NEXTBio Capital Management's ORIC Position: Q2 2026 in Review

NEXTBio Capital Management increased its Oric Pharmaceuticals (ORIC) stake by 35% in Q2 2026, buying an estimated $1.65M and bringing the position to 706,124 shares worth $7.65M. The position accounts for 3.52% of the portfolio, ranked #10.

NEXTBio Capital Management first reported a position in ORIC in Q4 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • NEXTBio Capital Management held 706,124 shares of Oric Pharmaceuticals worth $7.65M as of Q2 2026.
  • NEXTBio Capital Management bought 182,505 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Oric Pharmaceuticals made up 3.52% of NEXTBio Capital Management's portfolio in Q2 2026, its #10 holding.
  • NEXTBio Capital Management first reported a position in Oric Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.